Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-targeted mRNA vaccine
- Development stage
- Unknown
- Lead developer
- Chengdu Weisijin Biopharmaceutical Technology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The EBV-targeted mRNA vaccine is an investigational immunotherapy developed by West China Hospital of Sichuan University for the treatment of refractory Epstein-Barr virus (EBV)-associated malignancies. The vaccine utilizes messenger RNA (mRNA) technology to deliver genetic instructions for specific EBV antigens, such as LMP1, LMP2, or EBNA1, which are commonly expressed in EBV-positive tumor cells. Upon administration, the vaccine stimulates the patient's immune system to produce these viral proteins, thereby eliciting a targeted T-cell-mediated immune response against the tumor. It is currently being evaluated in Phase 1 clinical trials as a monotherapy and in combination with immune checkpoint inhibitors for indications including nasopharyngeal carcinoma, gastric cancer, and NK/T-cell lymphoma.
- Other names
- EBV-targeted mRNA vaccineEBV-mRNA vaccine
02
Targets
PSMB9 (Immunoproteasome subunit beta type-1i)
Beyond the preview
Go deeper on EBV-targeted mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-targeted mRNA vaccine.